View Older Stories View More Recent Stories

May 13, 2019 04:10PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2019 04:09PM Form 13F-NT Atlas Venture Associates For: Mar 31
May 13, 2019 03:48PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 13, 2019 01:44PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 8, 2019 07:00AM IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre
May 7, 2019 08:00AM Kyn Therapeutics Strengthens Leadership Team with Key Appointments
May 7, 2019 08:00AM Science2Startup Symposium Convened Close to 300 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections to Advance Scientific Innovation and Entre
Apr 18, 2019 08:00AM Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
Apr 18, 2019 07:00AM Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer
Apr 12, 2019 07:00AM Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
Apr 3, 2019 06:30AM Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
Apr 1, 2019 05:00AM Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million
Apr 1, 2019 02:28AM Novartis to pay $310 million for assets from inflammation specialist IFM
Apr 1, 2019 01:15AM Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Mar 28, 2019 07:00AM IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427
Mar 22, 2019 05:04PM Form 4 Magenta Therapeutics, For: Mar 20 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Feb 14, 2019 05:38PM Form 4 Replimune Group, Inc. For: Feb 12 Filed by: Atlas Venture Fund X, L.P.
Feb 14, 2019 06:00AM Cadent Therapeutics Appoints Jodie Morrison as Chief Executive Officer
Feb 13, 2019 04:27PM Form SC 13G Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 13, 2019 04:27PM Form SC 13G AVROBIO, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 13, 2019 04:27PM Form SC 13G Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 12, 2019 02:59PM Form 13F-NT ATLAS VENTURE FUND VI For: Dec 31
Feb 12, 2019 02:58PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 12, 2019 02:58PM Form 13F-NT Atlas Venture Associates For: Dec 31
Feb 11, 2019 11:24AM Form SC 13G Carbon Black, Inc. Filed by: Atlas Venture Associates VI, L.P.
Feb 8, 2019 01:51PM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Feb 8, 2019 06:20AM Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G/A Intellia Therapeutics, Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G Unum Therapeutics Inc. Filed by: Atlas Venture Fund IX, L.P.
Feb 8, 2019 06:20AM Form SC 13G Translate Bio, Inc. Filed by: Atlas Venture Fund VIII, L.P.
Feb 8, 2019 06:20AM Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
Feb 6, 2019 03:45PM Form 13F-HR Atlas Venture Associates For: Dec 31
Feb 4, 2019 07:00AM Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer
Jan 28, 2019 08:00AM Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO
Jan 23, 2019 07:00AM Schrödinger Appoints Veteran Biotech Industry Leader Dr. Rosana Kapeller to Board of Directors
Jan 18, 2019 07:02AM Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene (CELG)
Jan 18, 2019 07:00AM Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
Jan 3, 2019 08:00AM Nimbus Therapeutics Strengthens Leadership Team
Jan 2, 2019 01:47PM Form D/A Atlas Venture Opportunit
Jan 2, 2019 06:50AM Atlas Venture Announces $250 Million Opportunity Fund
Dec 17, 2018 09:05AM Generation Bio to Appoint Tom Graney as Chief Financial Officer
Dec 12, 2018 07:00AM Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases
Dec 6, 2018 08:00AM Akero Therapeutics Appoints Mark Iwicki to its Board of Directors
Dec 6, 2018 05:56AM miRagen Therapeutics (MGEN) Appoints Jeff Hatfield to Succeed Dr. Bruce Booth as New Board Chairman
Dec 5, 2018 04:05PM miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
Nov 29, 2018 10:56AM Form D Atlas Venture Opportunit
Nov 29, 2018 07:00AM Successful Seven-figure Funding Round for Provider of SaaS Customer Loyalty Platform: Loyalty Prime Intensifies Its International Growth
Nov 27, 2018 08:00AM Biotech Showcase™ Highlights Six Therapeutic Areas Garnering Attention for Investment in 2019
Nov 19, 2018 12:24PM Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform
View More Recent Stories View Older Stories